Undervalued, I couldn't agree more as I find myself doing
Undervalued, I couldn't agree more as I find myself doing the same thing. Smart folks have just a short window now to join the SFOR train at these levels. Even if the 3rd quarter revenue isn't good or what we hope for (it's funny, even if it is considered good it is really pocket change!)...it doesn't matter anymore with the IPR dismissal and settlement/s. Real revenues from deals are coming in very short order. Mark has told us this now several times. He is talking about uplisting the stock which to me is a big deal. It tells us how he feels about the upcoming tital wave. The naysayers will try to use the 3rd quarter (if it is even low revenue-hopefully we're pleasantly surprised) to sustain a last ditch effort but I don't see it. Who are they going to scare into selling????
There will be perceptive investors that realize what is going on here. I am just waiting for some high powered folks to want to get a good position over the next couple of weeks at the very end of the line.
What we should be telling Mark Kay is...don't uplist to the OTCQB Mark...just wait for the Nasdaq!!...LOL
3
Zerify Inc (ZRFY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...
Continue Reading
Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....
Continue Reading
Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...
Continue Reading
Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...
Continue Reading
Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...
Continue Reading
